AB Science S.A. (OTCMKTS:ABSCF – Get Free Report) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 140,570 shares, an increase of 805.3% from the May 14th total of 15,528 shares. Based on an average trading volume of 43 shares, the short-interest ratio is currently 3,269.1 days.
AB Science Price Performance
ABSCF opened at $1.12 on Wednesday. AB Science has a fifty-two week low of $1.12 and a fifty-two week high of $1.37. The business has a 50-day moving average of $1.25 and a 200-day moving average of $1.35.
About AB Science
AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr.
Featured Articles
- Five stocks we like better than AB Science
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
